



Atty. Dkt. N . 018733/0996

Re-Annot
#4/A
DT
11-27-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Shui-on LEUNG *et al.*

Title: IMMUNOCONJUGATES AND HUMANIZED ANTIBODIES
SPECIFIC FOR B-CELL LYMPHOMA AND LEUKEMIA CELLS

Appl. No.: 09/741,843

Filing Date: December 22, 2000

Examiner: Not Yet Assigned

Art Unit: Not Yet Assigned

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the present Continuation Application, Applicants respectfully request that the above-identified prior application be amended as follows:

In the Claims:

Please cancel claims 1-24 without prejudice or disclaimer and add the following new claims.

25. (New) A LL2 monoclonal antibody (mAb) or fragment thereof, comprising:
- a) the complementarity-determining regions (CDRs) of mouse LL2 (mLL2), wherein said LL2 mAb or fragment thereof retains substantially the B-lymphoma cell and leukemia cell targeting and cell internalization characteristics of said mLL2 mAb, and wherein the CDRs of the light chain variable region of mLL2 comprise CDR1 comprising amino acids 24 to 40 of SEQ ID NO: 2, CDR2 comprising amino acids 56 to 62 of SEQ ID NO: 2 and CDR3 comprising 95 to 103 of SEQ ID NO: 2 and the CDRs of the heavy chain variable region